Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer

Mazières, Julien; K. Paik, Paul; Chiara Garassino, Marina; Le, Xiuning; Sakai, Hiroshi; Veillon, Rémi; F. Smit, Egbert; B. Cortot, Alexis; Raskin, Jo; Viteri, Santiago; Wu, Yi‐Long; Chih‐Hsin Yang, James; Ahn, Myung‐Ju; Ma, Rui; Zhao, Jun; O’Brate, Aurora; Berghoff, Karin; Bruns, Rolf; Otto, Gordon; Johne, Andreas; Felip, Enriqueta; Thomas, Michael

doi:10.1001/jamaoncol.2023.1962

Public

Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer

Published in JAMA Oncology • Jun 4, 2023

Authors:

Julien Mazières

Paul K. Paik

Marina Chiara Garassino

Abstract

Importance: MET inhibitors have recently demonstrated clinical activity in patients with MET exon 14 (METex14)-skipping non-small cell lung cancer (NSCLC); however, data with longer follow-up and in larger populations are needed to further optimize therapeutic approaches. Objective: To assess the lo...

Subject

Medicine

Internal medicine

Cohort

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!